Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $34,533.36 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 47,963 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $0.72, for a total transaction of $34,533.36. Following the transaction, the director owned 1,679,330 shares in the company, valued at approximately $1,209,117.60. The trade was a 2.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total transaction of $69,650.76.
• On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.85, for a total value of $45,849.00.

Werewolf Therapeutics Stock Down 4.6%

HOWL stock traded down $0.03 during midday trading on Monday, hitting $0.69. The company’s stock had a trading volume of 199,935 shares, compared to its average volume of 410,071. The stock has a market cap of $33.53 million, a price-to-earnings ratio of -0.51 and a beta of 0.41. The stock’s 50-day moving average price is $0.81 and its 200 day moving average price is $0.88. Werewolf Therapeutics, Inc. has a 1 year low of $0.53 and a 1 year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.14. As a group, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on HOWL. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Susquehanna International Group LLP grew its holdings in shares of Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares in the last quarter. Vontobel Holding Ltd. lifted its position in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares during the last quarter. Regal Investment Advisors LLC lifted its position in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares during the last quarter. Bank of America Corp DE lifted its position in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after buying an additional 25,882 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in Werewolf Therapeutics in the 2nd quarter worth approximately $48,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.